Yes, you can submit multiple applications if they fall within the above focus areas and evaluation criteria. Please note that each application is associated with one email address. Therefore, please use different email addresses if you are making more than one application.

We do not have any limit on the number of awardees per problem statement. The final funding decision on proposals will be purely assessed on merit.

India Health Fund and partners do not suggest any funding (grant and/or equity) size for the proposals submitted through the RFP. The financial ask should be realistic and in alignment with the proposed work. The decision to approve the funding request, periodicity, and the conditions of disbursements lie solely with IHF and partners.

IHF and partners are strong believers of collaborative funding models to bring about bigger impact and a multiplier effect in the infectious disease ecosystem. The proportion of co-funding and support sought from IHF, and partners will be assessed and may vary on a case-to-case basis. As an important part of the evaluation process, we request all applicants to keep IHF and partners updated on any existing co-funding and partnership efforts regarding the application. We value transparency in the funding process.

This request for proposal is meant for innovations at or above TRL-5. Therefore, funding can be utilized for product/technology development, clinical testing and validation, commercial validation, and associated expenses for the same (e.g. labour and talent, consumables, equipment, project-related travel, etc.). The funding should solely be used for restricted work within the focus areas mentioned.

Due diligence includes a holistic evaluation of your organization and application. It will cover aspects including, but not limited to, technical and operational feasibility and rationality, the progress of clinical study, financial assessment, and refinement of the business model. It will also include reflecting on the long-term vision, goal, and intermediary outcomes envisaged in the proposal, project implementation plan, and competence of the applicant. Due diligence may require multiple iterations between IHF & partners, technical experts, external independent auditors, who may be hired to assist in the process, and applicants. Awards will be announced purely on merit basis and after completion of a rigorous due diligence process. Mere satisfactory completion of due diligence does not entitle an applicant to funding and support.

No. Once shortlisted, applicant organizations will have to produce relevant supporting documents to support their registration status, without which the application will not move through the selection process. 

TRL 9 – Technology has been applied in its final form and is operational.

TRL 8 – Technology is proven and developed but not yet operational or applied anywhere. 

TRL 7 – Actual system prototype is near completion or ready and has been demonstrated in an operational environment or is at pilot level.

TRL 6 – The prototype is being tested in a simulated operational environment or a high-fidelity laboratory environment.

TRL 5 – Technology has been put together and can be tested in a simulated environment.

TRL 4 – Basic technological components have been integrated to establish that they work together.

TRL 3 – Proof-of-Concept stage / Active R&D/ Advanced prototype has been initiated. This includes analytical studies and laboratory studies to physically validate the analytical predictions of separate elements of the technology.

TRL 2 – Technology concept/application formulated.

TRL 1 – There are research articles to support the technology’s basic properties.